Browsing Tag
Eli Lilly and Company
140 posts
Lilly’s oral GLP-1 pill cuts blood sugar and weight without injections—Here’s what the breakthrough data shows
Lilly’s oral GLP-1 drug orforglipron showed strong A1C and weight loss results in Phase 3—find out how it could change diabetes care worldwide.
Top stock market trends – Eli Lilly jumps $105, Hertz explodes 44%, Trump Media rallies again
Explore why Hertz, Eli Lilly, and Trump Media led the top U.S. stock market gainers on April 17, 2025. Get key data, economic context, and investor insights now.
Lilly’s lepodisiran shows 94% reduction in lipoprotein(a), offering hope for cardiovascular risk management
Lilly’s lepodisiran slashed lipoprotein(a) by 94% in a Phase 2 trial. See how this breakthrough could change cardiovascular disease treatment.
Hope for alopecia patients? Lilly’s baricitinib delivers significant hair regrowth in adolescents
Eli Lilly and Company (Lilly), in collaboration with Incyte, has reported significant progress in the treatment of severe…
Lilly’s Jaypirca moves closer to European approval for relapsed chronic lymphocytic leukemia
Eli Lilly and Company (Lilly) has moved one step closer to securing European approval for its targeted blood…
Inside Lilly’s $50bn push to transform American drug production
Eli Lilly and Company (Lilly) has unveiled an ambitious plan to more than double its U.S. manufacturing investment,…
More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment
Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay…
Eli Lilly acquires Organovo’s FXR program to advance IBD drug development
In a significant industry development, Eli Lilly and Company has acquired Organovo Holdings, Inc.’s FXR program, including its…
Eli Lilly sets 2024 revenue at $45bn amid revised guidance
Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion,…
Eli Lilly acquires promising PI3Kα inhibitor from Scorpion Therapeutics
Eli Lilly and Company (Lilly) has announced a significant acquisition of Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program, a…